Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fees: API Manufacturers To Pay Less Than Finished Dose Firms

Executive Summary

FDA and industry have agreed to create separate tiers for the charges that active pharmaceutical ingredient manufacturers and finished dosage form manufacturers will pay as part of a generic drug user fee program.
Advertisement

Related Content

Generic Drug User Fees Will Begin With The Backlog
Generic Drug User Fees Will Begin With The Backlog
FDA, Industry Reach Agreement On Major Portions Of Generic User Fee Program
Generic User Fee Talks: Performance Metrics For Early Years Still Unresolved
Generic User Fee Talks: Performance Metrics For Early Years Still Unresolved
ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point
ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point
Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation
Generic User Fee Negotiators Struggling To Meet June Deadline

Topics

Advertisement
UsernamePublicRestriction

Register

PS053510

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel